icone plus
Contact Abonnez-vous aux actualités
Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
minor
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique.
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
yuwtUBDNZSScWZ5E
Listen
